Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EGRX 
Eagle Pharmaceuticals Inc (EGRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: EGRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17
1 Year Target Price $17
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.59% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.27M USD | Price to earnings Ratio 3.76 | 1Y Target Price 17 |
Price to earnings Ratio 3.76 | 1Y Target Price 17 | ||
Volume (30-day avg) 1 | Beta 0.89 | 52 Weeks Range 0.00 - 4.57 | Updated Date 09/16/2025 |
52 Weeks Range 0.00 - 4.57 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.64% | Operating Margin (TTM) 15.94% |
Management Effectiveness
Return on Assets (TTM) 6.63% | Return on Equity (TTM) 4.88% |
Valuation
Trailing PE 3.76 | Forward PE 11.34 | Enterprise Value 41595908 | Price to Sales(TTM) 0.16 |
Enterprise Value 41595908 | Price to Sales(TTM) 0.16 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 1.75 | Shares Outstanding 12958200 | Shares Floating 4517258 |
Shares Outstanding 12958200 | Shares Floating 4517258 | ||
Percent Insiders 11.64 | Percent Institutions 55.2 |
Upturn AI SWOT
Eagle Pharmaceuticals Inc
Company Overview
History and Background
Eagle Pharmaceuticals Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey. The company focuses on developing and commercializing innovative pharmaceutical products, primarily through the FDA's 505(b)(2) regulatory pathway.
Core Business Areas
- Critical Care: Developing and commercializing injectable products for critical care settings.
- Oncology: Developing and commercializing injectable products for oncology treatments.
- Orphan Diseases: Targeting rare diseases with unmet medical needs.
Leadership and Structure
Scott Tarriff serves as the Chief Executive Officer. The company operates with a functional structure, with departments specializing in research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- BENDEKAu00ae: A bendamustine hydrochloride injection used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Competitors include generic bendamustine products. Revenue from BENDEKAu00ae has fluctuated due to generic competition.
- BELRAPZOu00ae: Another bendamustine hydrochloride injection. Competitors include generic bendamustine products. Revenue from BELRAPZOu00ae has fluctuated due to generic competition.
- Vasopressin: A vasopressin injection indicated for use in adults to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and vasopressors. The market is competitive. Competitors include Fresenius Kabi, Hikma Pharmaceuticals and generic vasopressin.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Specialty pharmaceutical companies like Eagle face challenges in bringing novel products to market and maintaining market share in the face of generic competition.
Positioning
Eagle Pharmaceuticals Inc. positions itself as a specialty pharmaceutical company focused on injectable products and leveraging the 505(b)(2) regulatory pathway to expedite drug approval.
Total Addressable Market (TAM)
The total addressable market is large and varies by product, focusing on specialty injectables. Eagle Pharmaceuticals Inc. targets niche segments, positioning itself to capture a portion of the broader pharmaceutical market.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on injectable products
- Utilization of 505(b)(2) regulatory pathway for faster approval
- Established commercial infrastructure
Weaknesses
- Reliance on a limited number of products
- Exposure to generic competition
- Dependence on partnerships for development and commercialization
- Fluctuations in revenue and profitability
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and collaborations
- Development of novel formulations and delivery systems
- Penetration of international markets
Threats
- Increasing generic competition
- Changes in regulatory environment
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- PFE
- Mylan
- HIKMA
Competitive Landscape
Eagle faces intense competition from both generic and branded pharmaceutical companies. Its competitive advantage lies in its ability to develop and commercialize niche injectable products.
Major Acquisitions
Arsia Therapeutics
- Year: 2016
- Acquisition Price (USD millions): 30
- Strategic Rationale: Enhanced pipeline with additional injectable products and delivery technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends depend on product performance and market conditions. Growth has been uneven due to generic entry.
Future Projections: Future projections depend on new product launches and the success of existing products. Analyst estimates would provide a more detailed outlook.
Recent Initiatives: Recent initiatives may include new product development, partnerships, and cost-cutting measures.
Summary
Eagle Pharmaceuticals is a specialty pharmaceutical company with potential, but it faces significant challenges. While its focus on injectables and utilization of the 505(b)(2) pathway offer advantages, reliance on a limited number of products and exposure to generic competition pose risks. Future growth depends on successful product launches, strategic partnerships, and effective cost management. Eagle must navigate a complex and competitive market to sustain long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports (FactSet, Bloomberg)
- Industry News and Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company-specific factors can change rapidly, impacting the accuracy of the data. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eagle Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Woodcliff Lake, NJ, United States | ||
IPO Launch date 2014-02-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 134 | Website https://www.eagleus.com |
Full time employees 134 | Website https://www.eagleus.com | ||
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.